Immune checkpoint inhibitors for cancer treatment

Area of Science:

• Immunology
• Oncology
• Pharmacology

Background:

• T cells are crucial for immune responses but require regulation to prevent excessive activity.
• Immune checkpoints, including inhibitory receptors and regulatory T cells, control T cell responses.
• Persistent antigens in chronic infections and cancer can lead to T cell exhaustion via these checkpoints.

Purpose of the Study:

• To review key receptors functioning as immunological checkpoints.
• To describe pharmaceutical agents targeting these immune checkpoints.
• To highlight the therapeutic potential of immune checkpoint inhibitors in cancer treatment.

Main Methods:

• Literature review of immunological checkpoint mechanisms.
• Analysis of drug development targeting cytotoxic T lymphocyte associated protein-4 (CTLA-4) and programmed cell death 1 (PD-1).
• Discussion of anti-CTLA-4 and anti-PD-1/PD-L1 antibodies as immune checkpoint inhibitors.

Main Results:

• Cytotoxic T lymphocyte associated protein-4 (CTLA-4) and programmed cell death 1 (PD-1) are critical immune checkpoint receptors.
• Immune checkpoint inhibitors, such as anti-CTLA-4 and anti-PD-1 antibodies, have been developed.
• These inhibitors are utilized in cancer therapy to overcome T cell exhaustion.

Conclusions:

• Immune checkpoints play a vital role in immune homeostasis and T cell regulation.
• Targeting immune checkpoints represents a significant advancement in cancer immunotherapy.
• Further research into immune checkpoint mechanisms and targeted therapies is warranted.